388 related articles for article (PubMed ID: 15385631)
1. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.
Austin CD; De Mazière AM; Pisacane PI; van Dijk SM; Eigenbrot C; Sliwkowski MX; Klumperman J; Scheller RH
Mol Biol Cell; 2004 Dec; 15(12):5268-82. PubMed ID: 15385631
[TBL] [Abstract][Full Text] [Related]
2. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.
Raja SM; Clubb RJ; Bhattacharyya M; Dimri M; Cheng H; Pan W; Ortega-Cava C; Lakku-Reddi A; Naramura M; Band V; Band H
Cancer Biol Ther; 2008 Oct; 7(10):1630-40. PubMed ID: 18769124
[TBL] [Abstract][Full Text] [Related]
3. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.
Zhang J; Liu S; Li Q; Shi Y; Wu Y; Liu F; Wang S; Zaky MY; Yousuf W; Sun Q; Guo D; Wang T; Zhang Y; Wang Y; Li M; Liu H
Cell Death Differ; 2020 Sep; 27(9):2710-2725. PubMed ID: 32327714
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments.
Cortese K; Howes MT; Lundmark R; Tagliatti E; Bagnato P; Petrelli A; Bono M; McMahon HT; Parton RG; Tacchetti C
Mol Biol Cell; 2013 Jan; 24(2):129-44. PubMed ID: 23154999
[TBL] [Abstract][Full Text] [Related]
6. Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.
Barr DJ; Ostermeyer-Fay AG; Matundan RA; Brown DA
J Cell Sci; 2008 Oct; 121(Pt 19):3155-66. PubMed ID: 18765569
[TBL] [Abstract][Full Text] [Related]
7. A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.
Bailey TA; Luan H; Tom E; Bielecki TA; Mohapatra B; Ahmad G; George M; Kelly DL; Natarajan A; Raja SM; Band V; Band H
J Biol Chem; 2014 Oct; 289(44):30443-30458. PubMed ID: 25225290
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate.
Mandler R; Dadachova E; Brechbiel JK; Waldmann TA; Brechbiel MW
Bioorg Med Chem Lett; 2000 May; 10(10):1025-8. PubMed ID: 10843208
[TBL] [Abstract][Full Text] [Related]
9. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.
Dokmanovic M; Hirsch DS; Shen Y; Wu WJ
Mol Cancer Ther; 2009 Jun; 8(6):1557-69. PubMed ID: 19509242
[TBL] [Abstract][Full Text] [Related]
10. Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.
Austin CD; Wen X; Gazzard L; Nelson C; Scheller RH; Scales SJ
Proc Natl Acad Sci U S A; 2005 Dec; 102(50):17987-92. PubMed ID: 16322102
[TBL] [Abstract][Full Text] [Related]
11. Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way.
Lerdrup M; Hommelgaard AM; Grandal M; van Deurs B
J Cell Sci; 2006 Jan; 119(Pt 1):85-95. PubMed ID: 16352662
[TBL] [Abstract][Full Text] [Related]
12. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
13. Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.
Lerdrup M; Bruun S; Grandal MV; Roepstorff K; Kristensen MM; Hommelgaard AM; van Deurs B
Mol Biol Cell; 2007 Sep; 18(9):3656-66. PubMed ID: 17626164
[TBL] [Abstract][Full Text] [Related]
14. Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells.
Castagnola P; Bellese G; Birocchi F; Gagliani MC; Tacchetti C; Cortese K
Oncotarget; 2016 Dec; 7(51):85411-85429. PubMed ID: 27863425
[TBL] [Abstract][Full Text] [Related]
15. The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells.
Ram S; Kim D; Ober RJ; Ward ES
MAbs; 2014; 6(5):1211-9. PubMed ID: 25517306
[TBL] [Abstract][Full Text] [Related]
16. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Xu W; Yuan X; Jung YJ; Yang Y; Basso A; Rosen N; Chung EJ; Trepel J; Neckers L
Cancer Res; 2003 Nov; 63(22):7777-84. PubMed ID: 14633703
[TBL] [Abstract][Full Text] [Related]
17. Use of an antibody to target geldanamycin.
Mendelsohn J
J Natl Cancer Inst; 2000 Oct; 92(19):1549-51. PubMed ID: 11018081
[No Abstract] [Full Text] [Related]
18. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.
Longva KE; Pedersen NM; Haslekås C; Stang E; Madshus IH
Int J Cancer; 2005 Sep; 116(3):359-67. PubMed ID: 15800944
[TBL] [Abstract][Full Text] [Related]
19. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
Friedländer E; Arndt-Jovin DJ; Nagy P; Jovin TM; Szöllosi J; Vereb G
Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
[TBL] [Abstract][Full Text] [Related]
20. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
Nagy P; Friedländer E; Tanner M; Kapanen AI; Carraway KL; Isola J; Jovin TM
Cancer Res; 2005 Jan; 65(2):473-82. PubMed ID: 15695389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
